SUCCESSFUL TREATMENT FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME IN A PUERPERA

SUCCESSFUL TREATMENT FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME IN A PUERPERA

Objective: to show the problems of differential diagnosis and treatment of atypical hemolytic-uremic syndrome in a 23-year-old patient.Results. Eculizumab (Soliris), (Alexon Pharmaceuticals Inc., USA) that is a glycosylated humanized monoclonal antibody to immunoglobulins (IgG2/4k) is shown to be ef...

Full description

Saved in:
Bibliographic Details
Main Authors: O. N. Ulitkina, Zh. S. Filippovskaya, E. I. Prokopenko, A. M. Ovezov, V. V. Likhvantsev
Format: Article
Language:English
Published: Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia 2016-01-01
Series:Общая реаниматология
Subjects:
atypical hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura, eculizumab (soliris), pregnancy
Online Access:https://www.reanimatology.com/rmt/article/view/1500
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items